reviewTop 1% cited

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer

Gynecologic Oncology · 2015 · Vol. 137(1) · pp. 173–179

Seiji Mabuchi✉(The University of Osaka)Hiromasa Kuroda(The University of Osaka)Ryoko Takahashi(The University of Osaka)Tomoyuki Sasano(The University of Osaka)

View via DOI Publisher page

PI3K/AKT/mTOR signaling in cancer Cancer Mechanisms and Therapy CRISPR and Genetic EngineeringPI3K/AKT/mTOR pathwayProtein kinase BMedicineCancer researchOvarian cancerRPTORCancerMetastasisSignal transductionInternal medicine

MeSH terms

Phosphoinositide-3 Kinase InhibitorsAnimalsFemaleHumansOvarian NeoplasmsSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesMolecular Targeted Therapy

Citations

409

FWCI

16.87

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review